Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1068-1071

  Al Hatmi, Abdullah M S ^a,b,c   Van Diepeningen, Anne D ^a   Curfs Breuker, Ilse ^d   Sybren de Hoog, G ^{a,b,e,f,g,h,i}   Meis, Jacques F ^d,j  

^a CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MINISTRY OF HEALTH   (Oman)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^f SUN YAT SEN UNIVERSITY   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Isavuconazole; Molecular identification; Multiresistant; Triazole agents

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NATAMYCIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; FUSARIUM; FUSARIUM ANANATUM; FUSARIUM ANDIYAZI; FUSARIUM ANTHOPHILUM; FUSARIUM FUJIKUROI; FUSARIUM NAPIFORME; FUSARIUM NYGAMAI; FUSARIUM PROLIFERATUM; FUSARIUM SACCHARI; FUSARIUM SUBGLUTINANS; FUSARIUM TEMPERATUM; FUSARIUM THAPSINUM; FUSARIUM VERTICILLIOIDES; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ANTIFUNGAL RESISTANCE; CLASSIFICATION; DRUG EFFECTS; FUSARIOSIS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; ENVIRONMENTAL MICROBIOLOGY; FUSARIOSIS; FUSARIUM; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84926505919     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku505     Document Type: Article

References (20)

1. Muhammed M, Coleman JJ, Carneiro HA et al. The challenge of managing fusariosis. Virulence 2011; 2: 91-6.
2. Tortorano AM, Richardson M, Roilides E et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect 2014; 20: 27-46.
3. Azor M, Gené J, Cano J et al. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother 2008; 52: 2228-31.
4. Cuenca-Estrella M, Gomez-Lopez A, Mellado E et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-21.
5. Lackner M, de Hoog GS, Verweij PE et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother 2012; 56: 2635-42.
6. Guarro J. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis 2013; 32: 1491-500.
7. van Diepeningen A, Al-Hatmi A, Brankovics B et al. Taxonomy and clinical spectra of Fusarium species: where dowe stand in 2014? Curr Clin Micro Rpt 2014; 1: 10-8.
8. Tortorano AM, Prigitano A, Esposto MC et al. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur J Clin Microbiol Infect Dis 2014; 33: 1623-30.
9. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antimicrobial Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38-A2. CLSI, Wayne, PA, USA, 2008.
10. Azor M, Gené J, Cano J et al. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother 2007; 51: 1500-3.
11. Raad I, Hachem R, Herbrech R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-403.
12. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-8.
13. Pujol I, Guarro J, Gené J et al. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997; 39: 163-7.
14. Muhammed M, Anagnostou T, Desalermos A et al. Fusarium infection. Medicine 2013; 92: 305-16.
15. Lewis RE, Wiederhold NP, Klepser ME et al. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 2005; 49: 945-51.
16. Sabatelli F, Pate RL, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
17. Sun CQ, Lalitha P, Prajna NV et al. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. Ophthalmology 2014; 121: 1495-500.
18. Guinea J, Pelaez T, Recio S et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52: 1396-400.
19. Lalitha P, Prajna N, Oldenburg C et al. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial. Cornea 2012; 31: 662-7.
20. Chowdhary A, Kathuria S, Xu J et al. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 2013; 9: e1003633.